Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin
and S-1 conversion therapy for initial unresectable local progression or potential resectable
metastatic gastric adenocarcinoma.